If you’re new to cannabidiol, you’ll want to start here. Cannabis is known to imbue a wide range of physiological effects. These effects come from a group of complex compounds known as cannabinoids. Scientists have identified over 100 different cannabinoids, but the two most well-known and well-researched are THC and CBD. CBD, or cannabidiol, has become increasingly popular as an ingredient in natural food supplements, offering a variety of potential effects that can benefit the body and mind. Take a look at this information to learn more about CBD.
People who experience psychosis may produce too much or even too little cannabinoids (from overactive dopamine receptors). CBD is milder than our internal cannabinoids and helps to re-establish a balance of cannabinoids in the brain. CBD also helps lower inflammation, which is often increased in schizophrenia. THC, on the other hand, is stronger than our internal cannabinoids (anandamide and 2-AG), this way potentially triggering psychosis [46, 48].
In 2019, the European Commission announced that CBD and other cannabinoids would be classified as "novel foods", meaning that CBD products would require authorization under the EU Novel Food Regulation stating: because "this product was not used as a food or food ingredient before 15 May 1997, before it may be placed on the market in the EU as a food or food ingredient, a safety assessment under the Novel Food Regulation is required." The recommendation – applying to CBD extracts, synthesized CBD, and all CBD products, including CBD oil – was scheduled for a final ruling by the European Commission in March 2019. If approved, manufacturers of CBD products would be required to conduct safety tests and prove safe consumption, indicating that CBD products would not be eligible for legal commerce until at least 2021.
The passage of the 2018 Farm Bill made it legal to sell hemp and hemp products in the U.S. But that doesn't mean that all hemp-derived cannabidiol products are legal. Since cannabidiol has been studied as a new drug, it can't be legally included in foods or dietary supplements. Also, cannabidiol can't be included in products marketed with therapeutic claims. Cannabidiol can only be included in "cosmetic" products and only if it contains less than 0.3% THC. But there are still products labeled as dietary supplements on the market that contain cannabidiol. The amount of cannabidiol contained in these products is not always reported accurately on the product label.
Hemp grown for industrial purposes may be treated with harsh chemicals and solvents in the manufacturing process, leaving any resulting hemp oil unfit for consumption. Because our hemp is grown in ideal conditions to produce our CBD hemp oil supplements, we never use harmful chemicals in our extraction process. Instead, we extract our hemp oil using supercritical CO2, which the FDA considers GRAS or generally regarded as safe. This chemical process allows us to ensure that our CBD hemp oil supplements are always free from contamination to best protect the health of your family.
While it was originally believed that THC is a breakdown product of CBD, it is now known that both THC and CBD are actually metabolites of their decarboxylated acidic forms, THCa and CBDa. These acidic precursors are decarboxylated (essentially dried) by heat or extraction to produce THC and CBD; only then do they become psychoactive.The compound has medicinal benefits without the “high” that some patients do not desire. This makes CBD appealing to patients who are looking for an alternative to their current meds, which often have opiate-like effects.
Cannabidiol has low affinity for the cannabinoid CB1 and CB2 receptors, although it can act as an antagonist of CB1/CB2 agonists despite this low affinity. Cannabidiol may be an antagonist of GPR55, a G protein-coupled receptor and putative cannabinoid receptor that is expressed in the caudate nucleus and putamen in the brain. It also may act as an inverse agonist of GPR3, GPR6, and GPR12. CBD has been shown to act as a serotonin 5-HT1A receptor partial agonist. It is an allosteric modulator of the μ- and δ-opioid receptors as well. The pharmacological effects of CBD may involve PPARγ agonism and intracellular calcium release. cannabidiol